Targeted Protein Degradation in Drug Discovery: PROTACs, Molecular Glues, Key Challenges and Best Practices
Targeted protein degradation is reshaping drug discovery by turning previously “undruggable” proteins into actionable therapeutic targets. This strategy harnesses the cell’s own quality-control machinery to remove disease-causing proteins rather than merely inhibit their activity, opening routes to treat oncology, neurodegeneration, infectious diseases, and more.How targeted degradation works
The core idea is to recruit an E3 ubiquitin ligase to a protein of interest so the ligase tags that protein with ubiquitin, marking it for destruction by the proteasome. Two major molecular classes exploit this concept: PROTACs (Proteolysis-Targeting Chimeras) and molecular glues. PROTACs are bifunctional molecules linking a ligand for the target protein to a ligand for an E3 ligase, connected by a linker whose length and flexibility are critical. Molecular glues are single small molecules that stabilize or induce a new interaction between an E3 ligase and the target, often offering simpler pharmacology and smaller molecular size.
Advantages over traditional inhibition
Targeted degradation can remove scaffolding proteins, transcription factors, and mutant proteins that resist conventional inhibitors.
Because degradation eliminates the protein, lower doses may sustain therapeutic effects longer and avoid rebound activity. Degraders can also overcome resistance mechanisms that upregulate target expression or mutate active sites.
Key technical challenges
– E3 ligase selection: Only a handful of E3 ligases are commonly used, so expanding the ligase toolkit is a major focus. Tissue-specific or disease-specific ligases could improve selectivity and safety.
– Cell permeability and pharmacokinetics: Bifunctional degrader molecules can be large and polar, complicating oral bioavailability and distribution. Linker design and scaffold optimization are crucial.
– Ternary complex dynamics: Effective degradation depends on a stable ternary complex between degrader, ligase, and target.
The so-called “hook effect” can reduce efficacy at high concentrations. Predicting and measuring ternary complex formation is essential.
– Resistance and selectivity: Cells may downregulate ligase expression or mutate degrader-binding sites. Off-target degradation risk must be evaluated carefully.
Best practices for discovery teams
– Prioritize structural and biophysical characterization: Co-crystal structures and cryo-EM of ternary complexes inform ligand placement and linker geometry.
– Use iterative SAR guided by degradation assays, not just binding affinity.
A strong binder may not induce degradation.
– Incorporate cellular readouts of ubiquitination and proteasome dependence alongside target protein levels to confirm mechanism.
– Optimize physicochemical properties early to improve ADME and enable convenient dosing routes.
– Explore nontraditional ligases and tissue-specific recruiters to widen therapeutic windows.
Emerging directions
Expanding beyond the proteasome, researchers are exploring lysosome-targeting chimeras for extracellular and membrane proteins. Degraders directed at neurodegenerative disease proteins, viral proteins, and immune modulators are advancing through translational pipelines with growing clinical attention.
Efforts to develop oral, brain-penetrant degraders and to pair degraders with biomarker-driven patient selection are increasing the translational potential.
Practical implications for drug development
For teams aiming to deploy degraders, integrating multidisciplinary capabilities—structural biology, medicinal chemistry, cell biology, and translational pharmacology—is essential. Early investment in assays that capture degradation kinetics, off-target profiles, and in vivo pharmacology will accelerate candidate selection and reduce downstream failures.
Targeted protein degradation represents a paradigm shift: by converting protein elimination into a druggable mechanism, it opens therapeutic opportunities across many disease areas while presenting unique design and translational challenges that discovery teams must strategically address.